Hormonal
Tirzepatide increases the risk of total adverse events (TAEs) and adverse events leading to discontinuation (DAEs) in a dose-dependent manner, with the 15mg dose having the highest risk.
Tirzepatide (TZP) comes with a higher risk of side effects, especially at the 15mg dose. These side effects, which often include gastrointestinal issues like nausea and vomiting, can lead to patients stopping the medication. The risk of these side effects increases with the dose. Patients with obesity may experience more side effects than those with T2DM. It is important to discuss these potential side effects with your doctor and monitor how your body responds to the medication.
Compared to placebo, insulin, and GLP-1RAs, TZP significantly increased TAEs in a dose-dependent manner... TZP significantly increased the risk of DAEs... TZP 15 mg was ranked first [for DAEs]...
Why this rating
Based on a Bayesian network meta-analysis of 14 RCTs with 14,654 participants.
Source
Tirzepatide cardiovascular benefits and adverse events assessment: a Bayesian network meta-analysis
xuyang gong et al. · Research Square · 2024
DOI 10.21203/rs.3.rs-4159026/v1
More from this paper
- Tirzepatide (TZP) reduces the risk of four-component major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes (T2DM) and obesity compared to placebo, with the 15mg dose showing the most significant reduction.Good
- Patients with Type 2 Diabetes Mellitus (T2DM) experience greater cardiovascular benefits and fewer adverse events from Tirzepatide compared to patients with obesity alone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →